文献速递生殖医学

不明原因不孕夫妇宫腔内人工授精的卵巢刺激策略:系统综述与个体参与者数据荟萃分析

Ovarian stimulation strategies for intrauterine insemination in couples with unexplained infertility: a systematic review and individual participant data meta-analysis.
PubMed 文献 · Hum Reprod Update · 2022-01-01

该系统综述与个体参与者数据荟萃分析纳入7项随机对照试验共2495对夫妇,比较促性腺激素、来曲唑和克罗米芬在宫腔内人工授精卵巢刺激中的有效性与安全性。促性腺激素较克罗米芬提高活产率(RR 1.30,95%CI 1.12-1.51)并缩短受孕时间(HR 1.37,95%CI 1.15-1.63),但增加多胎妊娠率(RR 2.17,95%CI 1.33-3.54)。

要点

  • 促性腺激素较克罗米芬提高活产率(RR 1.30,95%CI 1.12-1.51,中等确定性证据)。
  • 促性腺激素较克罗米芬增加多胎妊娠率(RR 2.17,95%CI 1.33-3.54,低确定性证据)。
  • 促性腺激素较克罗米芬缩短受孕至活产时间(HR 1.37,95%CI 1.15-1.63)。

核心结论

  • 在不区分取消标准或起始剂量的情况下,促性腺激素较克罗米芬提高活产率并缩短受孕时间,但多胎妊娠率更高。
  • 在采用较低起始剂量和更严格取消标准的现代实践中,不同药物的有效性和安全性似乎均可接受,临床决策应综合考虑干预措施的可及性、成本和患者偏好。
  • 由于与来曲唑比较的证据仅基于一项提供个体参与者数据的随机对照试验,需要进一步开展比较来曲唑与其他干预措施的随机对照试验。

研究设计与样本

  • 系统综述与个体参与者数据荟萃分析,检索MEDLINE、EMBASE、CENTRAL、CINAHL和PsycINFO从建库至2021年6月28日。
  • 纳入比较促性腺激素、来曲唑和克罗米芬用于不明原因不孕夫妇宫腔内人工授精卵巢刺激的随机对照试验。
  • 22项符合条件随机对照试验中7项(31.8%)提供个体参与者数据,共2495对夫妇(占22项随机对照试验3997对夫妇的62.4%),其中2411例不明原因不孕夫妇纳入本分析。
  • 6项随机对照试验(n=1511)比较促性腺激素与克罗米芬,1项(n=900)比较促性腺激素、来曲唑和克罗米芬。
  • 采用一阶段随机效应个体参与者数据荟萃分析。

主要发现

  • 促性腺激素较克罗米芬提高活产率(6项随机对照试验,2058名女性,RR 1.30,95%CI 1.12-1.51,I²=26%,中等确定性证据)。
  • 促性腺激素较克罗米芬可能增加多胎妊娠率(6项随机对照试验,2058名女性,RR 2.17,95%CI 1.33-3.54,I²=69%,低确定性证据)。
  • 多胎妊娠的异质性可由促性腺激素起始剂量和取消标准选择的差异解释。
  • 促性腺激素起始剂量较低(≤75 IU)的随机对照试验事后敏感性分析证实活产率较克罗米芬提高(5项随机对照试验,1457名女性,RR 1.26,95%CI 1.05-1.51)。
  • 仅纳入更严格取消标准随机对照试验的分析显示促性腺激素与克罗米芬活产率证据不确定(4项随机对照试验,1238名女性,RR 1.15,95%CI 0.94-1.41);多胎妊娠两项敏感性分析均显示不确定结果(RR 0.94,95%CI 0.45-1.96;RR 0.81,95%CI 0.32-2.03)。

临床怎么用

  • 在不明原因不孕夫妇宫腔内人工授精卵巢刺激中,促性腺激素较克罗米芬提高活产率并缩短受孕时间,但多胎妊娠率更高(不区分取消标准或起始剂量时)。
  • 在采用较低起始剂量和更严格取消标准的现代实践中,不同药物的有效性和安全性似乎均可接受,临床决策应综合考虑干预措施的可及性、成本和患者偏好。
  • 作者认为,由于与来曲唑比较的证据仅基于一项提供个体参与者数据的随机对照试验,需要进一步开展比较来曲唑与其他干预措施的随机对照试验。

局限性

  • 22项符合条件随机对照试验中仅7项(31.8%)提供个体参与者数据。
  • 与来曲唑比较的证据仅基于一项提供个体参与者数据的随机对照试验,需要进一步开展随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrauterine insemination with ovarian stimulation (IUI-OS) is a first-line treatment for unexplained infertility. Gonadotrophins, letrozole and clomiphene citrate (CC) are commonly used agents during IUI-OS and have been compared in multiple aggregate data meta-analyses, with substantial heterogeneity and no analysis on time-to-event outcomes. Individual participant data meta-analysis (IPD-MA) is considered the gold standard for evidence synthesis as it can offset inadequate reporting of individual studies by obtaining the IPD, and allows analyses on treatment-covariate interactions to identify couples who benefit most from a particular treatment. OBJECTIVE AND RATIONALE: We performed this IPD-MA to compare the effectiveness and safety of ovarian stimulation with gonadotrophins, letrozole and CC and to explore treatment-covariate interactions for important baseline characteristics in couples undergoing IUI. SEARCH METHODS: We searched electronic databases including MEDLINE, EMBASE, CENTRAL, CINAHL, and PsycINFO from their inception to 28 June 2021. We included randomized controlled trials (RCTs) comparing IUI-OS with gonadotrophins, letrozole and CC among couples with unexplained infertility. We contacted the authors of eligible RCTs to share the IPD and established the IUI IPD-MA Collaboration. The primary effectiveness outcome was live birth and the primary safety outcome was multiple pregnancy. Secondary outcomes were other reproductive outcomes, including time to conception leading to live birth. We performed a one-stage random effects IPD-MA. OUTCOMES: Seven of 22 (31.8%) eligible RCTs provided IPD of 2495 couples (62.4% of the 3997 couples participating in 22 RCTs), of which 2411 had unexplained infertility and were included in this IPD-MA. Six RCTs (n = 1511) compared gonadotrophins with CC, and one (n = 900) compared gonadotrophins, letrozole and CC. Moderate-certainty evidence showed that gonadotrophins increased the live birth rate compared to CC (6 RCTs, 2058 women, RR 1.30, 95% CI 1.12-1.51, I2 = 26%). Low-certainty evidence showed that gonadotrophins may also increase the multiple pregnancy rate compared to CC (6 RCTs, 2058 women, RR 2.17, 95% CI 1.33-3.54, I2 = 69%). Heterogeneity on multiple pregnancy could be explained by differences in gonadotrophin starting dose and choice of cancellation criteria. Post-hoc sensitivity analysis on RCTs with a low starting dose of gonadotrophins (≤75 IU) confirmed increased live birth rates compared to CC (5 RCTs, 1457 women, RR 1.26, 95% CI 1.05-1.51), but analysis on only RCTs with stricter cancellation criteria showed inconclusive evidence on live birth (4 RCTs, 1238 women, RR 1.15, 95% CI 0.94-1.41). For multiple pregnancy, both sensitivity analyses showed inconclusive findings between gonadotrophins and CC (RR 0.94, 95% CI 0.45-1.96; RR 0.81, 95% CI 0.32-2.03, respectively). Moderate certainty evidence showed that gonadotrophins reduced the time to conception leading to a live birth when compared to CC (6 RCTs, 2058 women, HR 1.37, 95% CI 1.15-1.63, I2 = 22%). No strong evidence on the treatment-covariate (female age, BMI or primary versus secondary infertility) interactions was found. WIDER IMPLICATIONS: In couples with unexplained infertility undergoing IUI-OS, gonadotrophins increased the chance of a live birth and reduced the time to conception compared to CC, at the cost of a higher multiple pregnancy rate, when not differentiating strategies on cancellation criteria or the starting dose. The treatment effects did not seem to differ in women of different age, BMI or primary versus secondary infertility. In a modern practice where a lower starting dose and stricter cancellation criteria are in place, effectiveness and safety of different agents seem both acceptable, and therefore intervention availability, cost and patients' preferences should factor in the clinical decision-making. As the evidence for comparisons to letrozole is based on one RCT providing IPD, further RCTs comparing letrozole and other interventions for unexplained infertility are needed.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Wessel JA, Danhof NA, van Eekelen R, et al. Ovarian stimulation strategies for intrauterine insemination in couples with unexplained infertility: a systematic review and individual participant data meta-analysis. Hum Reprod Update. 2022. PMID: 35587030. doi:10.1093/humupd/dmac021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。